Scientists probe hidden cell signals in diabetes
NCT ID NCT06976619
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how controlling blood sugar and using a GLP-1 drug (liraglutide) changes the way the pancreas works in people with type 1 or type 2 diabetes. Researchers will measure hormone levels before and after treatment. The goal is to understand how these treatments affect the body's natural GLP-1 system, not to cure or control the disease directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Blood test could predict who faces rapid kidney decline in diabetes
- Can an app and cash rewards tame type 1 diabetes in young adults?
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Can a single pill tackle both fatty liver and diabetes?